2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Small Cell Lung Carcinoma
9
Breast Neoplasms
8
Triple Negative Breast Neoplasms
7
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Lung Neoplasms
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Osteosarcoma
2
Uterine Cervical Neoplasms
1
Sarcoma, Ewing
1
Pathologic Complete Response
1
Neutropenia
1
Neoplasms
1
NSCLC
1
Myelosuppression
1
Limited Stage Small Cell Lung Cancer
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Advanced Squamous Non-Small-Cell Lung Cancer
1
Interventions
pembrolizumab
91
Gemcitabine
56
Nivolumab
50
Cisplatin
39
atezolizumab
37
Carboplatin
30
avelumab
29
enfortumab vedotin
25
Docetaxel
23
Magnetic Resonance Spectroscopy
19
Mitomycin
17
Ipilimumab
17
Paclitaxel
16
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
trilaciclib
×
Clear all
NCT04887831
2025-09-08
PRESERVE3
G1 Therapeutics, Inc.
Phase 2
Terminated
92 enrolled
24 charts